Halozyme Therapeutics (HALO) Tops Q1 EPS by 6c

Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $1.60, $0.06 better than the analyst estimate of $1.54. Revenue for the quarter came in at $377 million versus the consensus estimate of $358.45 million.

GUIDANCE:

Halozyme Therapeutics sees FY2026 EPS of $7.75-$8.25, versus the consensus of $8.09. Halozyme Therapeutics sees FY2026 revenue of $1.71-1.81 billion, versus the consensus of $1.76 billion.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Faraday Future stockholders approve $25M private placement proposal
• Meridian Reports Unaudited Half-Yearly Financial Results for the Six Months Ended 30 June 2026